(Q37912214)

25 August 2017

1 reference

title

Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? (English)

1 reference

25 August 2017

1 reference

3

Cees G M Kallenberg

1 reference

25 August 2017

Petra M Meiners

1

1 reference

25 August 2017

Arjan Vissink

series ordinal

2

1 reference

25 August 2017

Frans G M Kroese

series ordinal

4

1 reference

25 August 2017

Hendrika Bootsma

series ordinal

5

1 reference

25 August 2017

language of work or name

English

0 references

publication date

7 August 2011

1 reference

Expert Opinion on Biological Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1381-1394

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

25 August 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Increased Risk of Lymphoma in Sicca Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Therapeutic targeting of B cells for rheumatic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Treatment of primary Sjögren syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

CD20 deficiency in humans results in impaired T cell-independent antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab in Hodgkin lymphoma: is the target always a hit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Progression of salivary gland dysfunction in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Does rituximab increase the incidence of infectious complications? A narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

The future of biologic agents in the treatment of Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

BAFF: a local and systemic target in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Regulation of the B cell receptor repertoire and self-reactivity by BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

21 January 2018

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Autoimmune response and target autoantigens in Sjogren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

RETRACTED: Infliximab in primary Sjögren's syndrome: one-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.605352

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

21 January 2018

0 references

Identifiers

DOI

10.1517/14712598.2011.605352

1 reference

25 August 2017

1 reference